Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Metabolic & Endocrine/Diabetic Foot

Metabolic & Endocrine

Diabetic Foot

38

Pipeline Programs↗

67

Active Trials↗

51

Companies Involved↗

Diabetic Foot is a moderately active landscape with 38 programs across 51 companies. The most active players are Oneness Biotech Co., Ltd., Royal Biologics. 6 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

64/100

Pipeline Velocity

61/100

Mech. Concentration

100/100

Completion Rate

78/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Oneness Biotech Co., Ltd.

1 program

Royal Biologics

1 program

Pipeline

Programs by Phase

Preclinical20

Bupivacaine

Innocoll

Insulin

Merck & Co.

Sulfamethoxazole-Trimethoprim

National Institute of Allergy and Infectious Diseases (NIAID)

Antibiotic Duration

University Hospital, Geneva

Propolis

Indonesia University

Phase 15

Extracellular Vesicles

University of Jordan

Homsc200

Cytora Ltd.

Diabetic Foot Ulcer Treatment

Shanghai East Hospital

NOX1416 and SOC

NOxy Health Products, LLC

Placenta Stem Cells

Wake Forest University Health Sciences

Phase 27

Systemic Antibiotics

BioTissue Holdings, Inc

Allogeneic Mesenchymal Stem Cells

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

STIMULAN VG

Biocomposites Ltd

Adipose-Derived Regenerative Cells

Odense University Hospital

Topical Anti-Staphylococcus Bacteriophage Therapy

Centre Hospitalier Universitaire de Nīmes

Phase 36

Skinte

PolarityTE

Xianglei Tangzu Gao

Oneness Biotech Co., Ltd.

ENERGI-F703

Energenesis Biomedical Co., Ltd.

Yunnan Baiyao

Peking University Third Hospital

Amnio-Maxx Dual Layer Amnion

Royal Biologics

Approved

No programs

Analysis

Modality Breakdown

96%

Small molecule

24 of 25 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 25 classified programs, each share of the total. Modality classified for 92% of 38 pipeline programs.

Analysis

Trial Status

243

clinical trials

Completed108 · 44%

Unknown status36 · 15%

Recruiting30 · 12%

Terminated27 · 11%

Not yet recruiting22 · 9%

Active, not recruiting13 · 5%

Other7 · 3%

Clinical Trials

Trial Activity

243 trials

SMILE - TTT: Surgical MIcrovascularization of Lower Extremities for Diabetic Foot Ulcers - Transverse Tibial Transport Study

Recruiting·BBiodynamik, Inc·Preclinical·NCT07444593·100 enrolled

A Multicentric, Randomized, Controlled Clinical Trial Comparing High-Purity Type-I Collagen-Based Skin Substitute Versus Acellular Intact Fish Skin Matrix in the Treatment of Diabetic Foot Ulcers

Recruiting·Adichunchanagiri Institute of Medical Sciences, B G Nagara·Preclinical·NCT07781917·120 enrolled

Predictive and Diagnostic Biomarkers for Diabetic Foot Ulcers: Open Wound Master Study

Recruiting·UUniversity of Michigan·N/A·NCT06104969·5,000 enrolled

A Multicenter, Randomized Controlled Trial of VES-0-D Gel, an Investigational Alginol, Versus Standard Care in the Management of Wagner Grade 1 or 2 Diabetic Foot Ulcers Over 8 Weeks

Recruiting·FFlen Health·Preclinical·NCT07783087·64 enrolled

A Multicenter, Prospective, Randomized Controlled Modified Platform Trial Evaluating the Efficacy of Multiple Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Standard of Care Alone in the Treatment of Nonhealing Diabetic Foot Ulcers.

Recruiting·SSamaritan Biologics·Preclinical·NCT06437028·170 enrolled

Comprehensive Assistance and Resources for Effective Diabetic Foot Navigation (CARE-D-Foot-Nav), a Single-arm Pilot Study

Recruiting·EEmory University·Preclinical·NCT07143175·25 enrolled

A Prospective, Multi-center, Randomized, Double-blind, Controlled, Phase 1 Study of VELGRAFT, a Living Cellular Construct, in the Management of Chronic Diabetic Foot Ulcers Which Have Attained Granulation Tissue

Recruiting·AAyu, Inc.·Phase 1·NCT07498218·24 enrolled

A Prospective, Randomized, Single-Blind Phase 2a Multi-Center Dose Comparative Study to Evaluated The Safety, Tolerability, and Antimicrobial Efficacy Of Topically Twice Daily Applied Bisphosphocin Nu-3 Gel At a 2%, 5%, And 10% Concentration To Infected Diabetic Foot Ulcers (iDFU)

Recruiting·LLakewood-Amedex Inc·Phase 2·NCT07565506·24 enrolled

A Prospective, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of CYWC628 (Human Dermal Fibroblast Spheroids) for the Treatment of Refractory Diabetic Foot Ulcers Compared With Standard of Care

Recruiting·FFibroBiologics·Preclinical·NCT07096934·120 enrolled

The Effect of L-Carnitine on Wound Healing in Patients With Diabetic Foot Ulcer.

Recruiting·AAin Shams University·Phase 2·NCT07768228·50 enrolled

Diabetic Foot Ulcers: Shorter Treatment Period Using Custom Felt Relief?

Recruiting·HHelse Møre og Romsdal HF·Preclinical·NCT04058639·74 enrolled

A Randomized Controlled Multicenter Trial, Examining the Effect of Miro3D Wound Matrix on the Rate of Complete Wound Closure of Chronic Diabetic Foot Ulcers

Recruiting·RReprise Biomedical, Inc.·Preclinical·NCT07632001·180 enrolled

Effect of a Coordinated Primary-care-Based MDT-model on the Treatment of Hard-to-heal Ulcers; a Randomized Clinically Controlled Trial

Recruiting·NNordsjaellands Hospital·Preclinical·NCT07747896·80 enrolled

Evaluation of the Efficacy of Omeza® Complete Matrix in the Healing of Chronic Diabetic Foot Ulcers: A Randomized Controlled Multicenter Crossover Trial

Recruiting·OOmeza, LLC·Preclinical·NCT07161830·180 enrolled

Evaluating the Efficacy of Pulsating Electromagnetic Field (PEMF) Therapy for Diabetic Foot Ulcers Using the CRAD ULCER X-01 Device: A Randomised Parallel-Group Pilot Study

Recruiting·National Defence University of Malaysia·Preclinical·NCT07465640·32 enrolled

Page 1 of 17

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)